Archive for October, 2023

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria Findings to be Presented During Poster Session at Kidney Week 2023 SOUTH SAN FRANCISCO, CA., October 13, 2023–Maze Therapeutics, a company…

Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease Findings Published in JASN in Partnership with the Million Veteran Program and Vanderbilt University Medical Center SOUTH…